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A B S T R A C T
A targetedmass spectrometric assaywas developed for identiﬁcation and quantiﬁcation of apoE isoforms
(apoE2, E3 and E4), and it was utilized for screening of samples from AD patients (n =39) and patients
with other neurodegenerative disorders (n = 38). The assay showed good linearity with LOQ corresponds
to total apoE concentration of 0.8 and 40ng/mL in CSF and plasma/serum, respectively. We identiﬁed
apoE phenotypes with 100% accuracy in clinical samples. We found strong association between
genotypes of the individuals and their apoE levels in blood; e4 allele carriers had signiﬁcantly lower apoE
levels in blood than non-carriers.
ã 2015 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Alzheimer’s disease (AD) accounts for 60–70% of all cases of
dementia [1]. It is a chronic neurodegenerative disorder charac-
terized byneuronal degeneration, plaques composed of aggregated
b-amyloid (Ab) and tangles composed of hyperphosphorylated
tau protein [1].[21_TD$DIFF] Clinically, AD is characterized by an insidious onset
and slowly progressive symptoms in the form of memory
disturbances together with instrumental symptoms such as
aphasia, agnosia and apraxia [1].
The cause of AD is unknown but most data suggest that
aggregation of a 42 amino acid long amyloid b protein (Ab42) into
senile plaques in the brain extracellular matrix occurs very early
(10–20 years) before the ﬁrst symptoms appear and may be
pathogenic [2]. Genetic factors account for approximately 70% of
the risk [3] with the apolipoprotein E gene ([22_TD$DIFF]APOE) being the major
susceptibility gene for the sporadic form of the disease [4]. There
are three common [23_TD$DIFF]APOE alleles (e2, e3 and e4) that encode three
isoforms of the protein (E[24_TD$DIFF] , E3 and E4). ApoE isoforms differ from
each other by only one or two amino acids at positions 130 and 176
(112 and 158 in the mature protein) [5]. The E4 isoform appears to
facilitate Ab42 aggregation into senile plaques by reducing its
clearance [6], which is thought to be the underlyingmechanism for
the strong association of apoE e4 with AD.
Plaque pathology, neurodegeneration and neuroﬁbrillary tangle
pathology can be monitored using three cerebrospinal ﬂuid (CSF)
markers, namely CSF Ab42, total tau (T-tau) and phospho-tau (P-
tau), respectively [7]. Together, thesemarkers are 85–95% sensitive
and speciﬁc for AD in both pre-dementia and dementia stages of
the disease. However, to date there are only a few studies
investigation the association of CSF and plasma levels of apoE
isoforms in the context of AD [8–10]. Identiﬁcation and quantiﬁ-
cation of apoE4 in other matrices, such as astrocytes and brain
tissue was reported previously [11,12].
The current study describes the development of an apoE
isoform-speciﬁc mass spectrometry-based quantitative analysis.
Selective reaction monitoring (SRM) assay was established and
applied to CSF and blood samples from AD patients and patients
with other neurodegenerative disorders in order to identify apoE
phenotypes and quantify apoE levels including its speciﬁc
isoforms.
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2. Materials and methods
2.1. Signal peptide selection
Tryptic peptides unique for isoforms E2 (CLAVYQAGAR) and E4
(LGADMEDVR), and peptides common in all the three isoforms, in
total 9 sequences (Table 1), were selected as signal peptides and
used for the MRM assay development. Heavy peptides, isotope
labeled with 15N and 13C in lysine (Dmass = +8) and arginine
(Dmass = +10) of AQUA QuantPro quality (peptide purity higher
than 97%, concentrationprecision equal or better than25%), were
purchased from Thermo Fischer Scientiﬁc (Ulm, Germany). These
heavy isotope labeled peptides were spiked into the biological
samples at known concentrations and the ratio between endoge-
nous (light) and internal standard peptide was used to calculate
the concentration of apoE in the samples.
2.2. Clinical materials
Cohort A included plasma and cerebrospinal ﬂuid (CSF) samples
obtained at the Memory Clinic at Skåne University Hospital in
Malmö (Sweden) from subjects with either Alzheimer’s disease
(n=13) or individuals with subjective cognitive decline but no
dementia (SCD) diagnoses at sampling (n =12). Cohort B included
serum samples from AD patients (n =26) and patients with other
neurodegenerative diseases (n =25; 13 with mixed AD/vascular
dementia, 3 with vascular dementia, 3 with subjective memory
complaints, 2 with frontotemporal dementia, 2 with Lewy body
dementia, 1 with Parkinson’s disease and 1 with unspeciﬁed
dementia). See Table 4 for patient characteristics. The clinical
studies were approved by the Universities of Lund (Cohort A) and
Umeå (Cohort B). All study enrollments followed the recommen-
dations of the Declaration of Helsinki.
2.3. Sample preparation
100mL of CSF or 10mL of 10 times diluted plasma/serum were
diluted with 50mMAMBIC containing sodium deoxycholate (SDC)
in a ﬁnal concentration of 2m/v%; and reduced with 10mM
dithiothreitol (60min, 37 C) then alkylated with 50mM iodoace-
tamide (30min, at room temperature in dark). 50mM AMBIC was
added to the samples to reduce the SDC concentration to 0.5m/v%
before trypsin addition. The samples were digested with sequence
grade trypsin (ca.1:50 enzyme: total protein ratio) 18h at 37 C and
then the digestion was stopped by the addition of 10v/v% formic
acid. The acidiﬁed digests were centrifuged at room temperature
for 5min at 15,000 g to effectively pellet SDC and remove it from
the samples.
The digested samples were spiked with a mixture of heavy
isotope-labeled peptide standards and ﬁnally analyzed by nanoLC-
SRM/MS.
2.4. nanoLC-SRM/MS analysis
The SRM assay was performed on a TSQ Vantage mass
spectrometer equipped with an Easy n-LC II pump (Thermo
Scientiﬁc, Waltham, MA). Five microliter of plasma/serum digest
(4.5 nL plasma/serum equivalent) and 10mL of CSF digest (0.45mL
original CSF equivalent) were injected onto an Easy C18-A1 pre-
column (Thermo Scientiﬁc, Waltham, MA), and following on-line
desalting and concentration the tryptic peptideswere separated on
a 75mm150mm fused silica column packed in-house with
ReproSil C18 (3mm, 120Å from Dr. Maisch GmbH, Germany).
Separationswere performed in a 45-min linear gradient from 10 to
40% acetonitrile containing 0.1% formic acid; at the ﬂow rate of
300nL/min. The MS analysis was conducted with 1750V spray
voltage and 0V declustering potential. The transfer capillary
temperature was set to 270 C and S-lens RF amplitude was set to
143V. At least 3 transitions per target peptide were monitored in
scheduled SRM mode with 3-min detection windows. SRM
transitions were acquired in Q1 and Q3 operated at unit resolution
(0.7 FWHM), the collision gas pressure in [25_TD$DIFF]q2 was set to 1.2mTorr.
The cycle time was 1.5 s.
Identical SRM acquisition parameters were used for the heavy
and light forms of each peptide, while taking into account the Q1/
Q3 mass differences due to the stable isotope labeling. The three
transitions that produce the highest signals while still maintaining
the same relative intensities in both buffer and biological samples
were selected as the ﬁnal ion pairs for use for quantiﬁcation.
2.5. Data analysis
All raw data generated on the triple quadrupole mass
spectrometer were imported to Skyline v2.5 software (MacCoss
Lab.) for data analysis. Quantiﬁcation was based on the corre-
sponding light and heavy peak area ratios. The peak integration
was done automatically by the software, using Savitzky–Golay
smoothing, and all the data were manually inspected to conﬁrm
the correct peak detection. Further statistical analysis was done
usingMicrosoft Excel, R andMatlab v7.11 (Mathworks, Natick,MA).
3. Results and discussion
We have developed an SRM assay for the quantiﬁcation of apoE
isoforms by using a stable isotope dilution strategy. Isoform
speciﬁc sequences and sequences common in each isoform were
selected and synthesized in heavy formwith stable isotope labeled
C-terminal Arg or Lys. These peptides were used to optimize the
SRM assay parameters, such as, the chromatographic separation
and the selection of best transitions, free from interferences in
complex biological media. We investigated the assay performance
and the sample preparation in two biological matrices. The
developed assay has been utilized for screening of both blood and
CSF samples from AD and non-AD subjects; and additionally
statistical analysis were done to ﬁnd correlations between the
experimental and clinical data.
3.1. Reproducibility and precision of the assay
Both isoform speciﬁc peptides and peptides common in all apoE
isoforms (Table 1) were targeted in the assay in order to measure
the level of different isoforms and total apoE in biological samples.
For detailed information about the monitored transitions see
Supplementary Table 1.
The linearity of the SRM assay was determined by spiking a
mixture of heavy labeled internal standard (IS) peptides into a
pooled sample of 18 [26_TD$DIFF]CSF samples at 8 different levels. The analysis
of each sample was repeated 5 times and then the area ratios of
Table 1
ApoE peptides used for SRM assay development.
Position Sequence
94–108 SELEEQLTPVAEETR Common
122–132 LGADMEDVCGR E2, E3
122–130 LGADMEDVR E4
176–185 CLAVYQAGAR E2
177–185 LAVYQAGAR E3, E4
199–207 LGPLVEQGR Common
210–224 AATVGSLAGQPLQER Common
270–278 LQAEAFQAR Common
261–269 LEEQAQQIR Common
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heavy labeled standard and corresponding endogenous peakswere
plotted against the spiked IS concentrations (Supplementary
Fig. 1). Excellent linear regressions were achieved for each peptide
within the investigated concentration range (0.001–50 fmol/mL)
with LOQ varied in the attomolar range (4–80 attomoles on
column) (Supplementary Fig. 1). The LOQ of the apoE peptides by
SRM analysis was estimated as the lowest concentrationmeasured
with CV <20% in 5 replicates. The best peptide (LGPLVEQGR) was
used to calculate LOQ of the assay that corresponds to an apoE
concentration of 0.8 and 40ng/mL in CSF and plasma/serum,
respectively.
In order to evaluate the analytical performance of the SRM
assay, including tryptic digestion and sample spiking with IS
peptides we have investigated some key parameters.
The variation of the LC-MRM/MS analysis was determined in
6 randomly selected CSF and plasma samples analyzed in
triplicates. The CVs of the triplicate MS analyses ranged between
0.16% and 7.04% and the average was 2.28% in the overall dataset, [27_TD$DIFF]
i.e., in the 12 investigated samples. Table 2 shows the average CV
values for each peptide in the two different biologicalmatrices. The
reproducibility was slightly better in CSF for almost all peptides,
except CLAVYQAGAR. Considerably lower variations were detected
in CSF than in plasma with LGADMEDVCGR, LGADMEDVR and
LEEQAQQIR peptides that most probably due to the higher
complexity of plasma compared to CSF.
Digestion replicates were also generated by digesting three
individual aliquots from 5 selected CSF and plasma samples that
were spiked with a mixture of heavy IS peptides and analyzed by
nanoLC-MRM/MS. The overall variation of the sample processing
was less than 20% for all target peptides, and it was only a slight
difference between thedistinctpeptides inCSF (Table 2). In contrast,
two peptides (SELEEQLTPVAEETR and LEEQAQQIR) showed high
variability in the plasma samples. These two peptides seem to be
more sensitive to slight changes in the digestion conditions and
becauseof thehigher risk of imprecisionweexcluded them fromthe
ﬁnal quantiﬁcation. This ﬁnding is supported by our previous
experiment, where different enzyme: protein ratios were investi-
gated. We examined four different trypsin: protein ratios (1:100,
1:50, 1:25 and 1:12.5) and we found continuous increase in the
endogenouspeptidesignalsby increasing the trypsinamountonly in
thecaseof twopeptides(SELEEQLTPVAEETRandLEEQAQQIR), all the
other peptides gave approximately the same signals at different
conditions (Supplementary Fig. 2).
3.2. Quantiﬁcation of apoE isoforms and total apoE
The endogenous levels of apoE peptides were calculated by
taking the ratio between the peak areas of the endogenous (light)
and IS peptides (heavy) and correlate to the known concentration
of the heavy peptides that were spiked into the samples. The
calculations were made for each peptide individually.
Total apoE amounts were obtained in two different ways, (1) by
calculating directly from a peptide represents all the three
isoforms (LGPLVEQGR, AATVGSLAGQPLQER and LQAEAFQAR) or
(2) by adding the concentrations of each isoform (LGADMEDVCGR
(E2 and 3) + LGADMEDVR (E4) and LAVYQAGAR (E3 and 4) + CLAV-
YQAGAR (E2)). The linear regression coefﬁcients between total
apoE concentrations calculated by different peptides were excel-
lent with R2-values ranging between 0.75–0.97, however the
absolute amounts were slightly different. Fig. 1 shows some
examples of the correlations between different peptide signals in
CSF (A and B) in plasma (C and D) and in serum (E and F). For all
possible combinations see Supplementary Fig. 3. The differences
between peptides could be attributed to alterations in digestion
efﬁciency of different regions of apoE, and to variances of IS
peptide concentrations; according to the manufacturer the
concentration precision is equal or better than 25%.
The total apoE concentration achieved from the sumof peptides
LGADMEDVCGR and LGADMEDVR was lower than the sum of the
other two speciﬁc peptides LAVYQAGAR and CLAVYQAGAR in all
the three sample types, however they showed similar correlation
with other peptide signals (Supplementary Fig. 3). This data
suggest that using the signal of peptide LGADMEDVRwill lead to an
underestimation of the amount of apoE4 isoform. To address this
problem we calculated a correction factor for LGADMEDVR by
comparing the signals of LGADMEDVR (E4) and LAVYQAGAR
(E3 and 4) in E4/E4 homozygous individuals. A speciﬁc correction
factor was assigned to each sample type and used for calculation of
apoE4 concentration. The concentration of apoE2 was calculated
from the signal of peptide CLAVYQAGAR. Because there is no
isoform speciﬁc peptide available for apoE3, its amount was
calculated by subtracting the concentration of peptide LGAD-
MEDVR (apoE4) from peptide LAVYQAGAR (apoE3 and 4) in
samples with apoE3/E4 phenotypes, otherwise (for phenotypes
apoE3/E3 and E2/E3) LAVYQAGAR was used. Peptide LGAD-
MEDVCGR was used only for determination of the phenotypes.
See Supplementary Fig. 2 for the summary of apoE quantiﬁcation
in the two cohorts.
We further investigated the heterozygous individuals and
found very similar isoform distribution in heterozygous individu-
als to what it was reported formerly using a similar mass
spectrometry-based assay [13]. The distribution was 52/48%
between E3 and E4 isoforms in CSF in [28_TD$DIFF]APOE e3/4 individuals,
while in plasma and serum it was 66/34% and 63/37%, respectively.
ApoE2 and ApoE3 isoforms have almost equal contribution to the
total apoE level in plasma and serum in the heterozygous
Table 2
Analytical performance of the SRM assay in CSF and plasma.
Reproducibility of the MS analysis (average CV [15_TD$DIFF]%a) Reproducibility of the sample processing (average CV [16_TD$DIFF]%b)
CSF Plasma CSF Plasma
SELEEQLTPVAEETRc 1.30 1.98 6.41 19.95
LGADMEDVCGR 1.97 5.63 5.78 4.13
LGADMEDVR 0.43 3.03 4.00 7.65
CLAVYQAGAR 2.69 1.12 4.47 4.40
LAVYQAGAR 1.67 2.14 2.36 2.86
LGPLVEQGR 1.92 2.07 2.48 3.59
AATVGSLAGQPLQER 1.71 1.89 3.03 4.06
LQAEAFQAR 1.24 2.41 2.69 4.09
LEEQAQQIRc 2.51 4.18 3.37 10.44
a The CV value was calculated for each peptide based on triplicate MS analysis of 6 individual CSF and plasma samples.
b The CV was calculated for each peptide based on triplicate digestion of 5 individual CSF and plasma samples.
c Peptides excluded from the ﬁnal SRM assay.
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individuals (54/46% and 52/48%), while in CSF the proportion of
E3 isoform is more pronounced (61/39%). The differences in
isoform distribution in between CSF and blood, additionally the
lack of signiﬁcant association between CSF and plasma total apoE
levels support the concept [14] that apoE from blood does not
exchangewith apoE from brain because of the blood–brain barrier.
3.3. ApoE phenotypes and concentration in clinical samples
In this study we analyzed blood samples collected from two
cohorts of AD and non-AD subjects, additionally CSF samples from
patients belonging to the ﬁrst cohort were also analyzed.
In order to identify different phenotypes we monitored four
peptide signals (LGADMEDVCGR (apoE2 [29_TD$DIFF]and 3), LGADMEDVR
(apoE4), LAVYQAGAR (apoE3 and 4), CLAVYQAGAR (apoE2)) each
and every phenotype has a speciﬁc pattern (Supplementary Fig. 4)
that allows phenotyping of biological samples. We managed to
identify ﬁve different phenotypes (E2/E3, E2/E4 and E3/
E4 heterozygotes; additionally E3/E3 and E4/E4 homozygotes) in
our sample cohorts (four types in the ﬁrst cohort and 5 types in the
second cohort) (Table 3); our sample characterization matched
well with genotyping data, 100% agreement was found between
the two methods.
Our data generated from plasma samples belonging to the ﬁrst
cohort indicated a strong relationship between [30_TD$DIFF]APOE genotypes of
the subjects and their apoE levels in plasma. Patients carrying
e4 allele had signiﬁcantly lower apoE levels in blood than non-
carriers (Fig. 2A and B). The relationship between genotypes and
apoE levels was allele dose-dependent; more speciﬁcally the
protein level of apoE in e4 non-carriers was the highest, in
heterozygotes e4 carriers the expression was lower and in
homozygotes e4 carriers the expression was the lowest (e4/
 > e4/+ > e4+/+). In contrast there was no clear genotype-
dependent relationship in CSF (Supplementary Fig. 5).
[(Fig._1)TD$FIG]
Fig. 1. Correlations between total apoE concentrationsmeasured by different peptides in CSF (A and B), in plasma (C and D) and in serum (E and F). Total apoE concentrations
were achieved frompeptides, common in each apoE isoforms (LGPLVEQGR and LQAEAFQAR) or calculated by summing the signals of peptides representing different isoforms
(LAVYQAGAR (apoE3 and 4) + CLAVYQAGAR (apoE2)).
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In order to validate our observation on the apoE genotype
dependent relationship in blood, we analyzed another cohort
(cohort B) with a larger sample number. We detected similar
tendency in the apoE levels in relation to e4 allele carriers and non-
carriers in the second cohort (Fig. 2C and D). One outlier with e4/
e4 genotype, which gave extremely high total apoE concentration
(174.5mg/mL vs. 46.119.0mg/mL), was removed from the ﬁnal
statistical analysis.
This ﬁnding about the genotype dependence of apoE level in
blood is in agreement with previous studies [15,16,8,9]. Inconsis-
tent results were published previously in regard to apoE
concentration differences in CSF between different apoE genotypes
[17,18]. Our data showed no association between [31_TD$DIFF]APOE genotype
Table 3
ApoE phenotype frequencies in the two cohorts.
Study ID E4 freq. (%) E2/E3 E2/E4 E3/E3 E3/E4 E4/E4
Cohort A AD
n =13
62 2 – 3 4 4
Non-AD
n =13
38 3 – 5 4 1
Total 50 5 – 8 8 5
Cohort B AD
n =26
65 3 1 6 7 9
Non-AD
n =25
40 5 1 10 5 4
Total 53 8 2 16 12 13
[(Fig._2)TD$FIG]
Fig. 2. Total apoE concentration in plasma samples from cohort A (A and B) and in serum samples from cohort B (C andD). Samples are grouped byphenotypes on Fig 2A and C
(E2/E3: heterozygous apoE2/3 individuals, E2/E4: heterozygous apoE2/4 individuals, E3/E3: homozygous apoE3/3 individuals, E3/E4: heterozygous apoE3/4 individuals and
E4/E4: homozygous apoE4/4 individuals) and by e4 status on B and D (E4/: e4 non-carriers, E4/+: heterozygous e4 carriers, E4+/+: homozygous e4 carriers). Total apoE
concentration was calculated from the measured LGPLVEQGR peptide signal.
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and apoE level in CSF, which is in line with a previous study from
Martinez-Morillo et al. [9].
3.4. Comparison of apoE levels with clinical markers
We analyzed the relationship between clinical markers (T-tau,
P-tau and Ab42) of AD and the determined apoE levels in CSF and
blood, additionallywe investigated a possible link between clinical
diagnoses and apoE level. However, we are aware that the size of
our clinical cohorts may be too small to draw consistent
conclusions. The demographic data of subjects involved in this
study is presented in Table 4.
The role of apoE in AD pathogenesis is unquestionable, however
the results from studies considering apoE as potential biomarker
are inconsistent and contradictory. ApoE levels have been
measured both in CSF and in blood previously. Some studies
reported decreased apoE levels in AD patients in plasma [16,19]
and also in CSF [20], while elevated apoE levelswere alsomeasured
in AD [32_TD$DIFF] 21,22,16]. Additionally, some studies could not ﬁnd
differences between controls and AD patients [8,23,24]. The
contradictions may arise from the use of different methods,
variances in sample collection and handling or selection of the
patient cohorts.
Our results indicated no signiﬁcant differences of the apoE level
in between AD and non-AD groups neither in CSF nor in plasma
(p= 0.361, p= 0.333). The most probable explanation for the
inability to differentiate healthy from AD patients is the relatively
small sample number and the large heterogeneity within groups.
The unequal gender distribution between control and AD group
may also be a possible cause, as higher blood apoE level was
previously reported in females older than 50 [8,25]. Our results
also showed slightly higher apoE concentrations in female subjects
(35.7 vs. 33.24mg/mL), although this was not signiﬁcant. The
analysis of the second cohort showed the same results, [27_TD$DIFF]i.e., no
alterations in apoE level between the two patient groups
(p = 0.244). These results conﬁrm the previous reports that the
determination of total apoE bioﬂuid level itself is not supporting
the Alzheimer’s diagnosis [8,24,26].
We found that total apoE concentrations in CSF were positively
associatedwithCSFP-tau ine4non-carriers (s =0.881,p= 0.027)but
not in e4 carriers (s =0.104, p = 0.737). This ﬁnding is inconsistent
with previous publications [9,27], where genotype independent
correlationswere reportedbetweenCSFapoEandtau levels (bothT-
andP-tau). Further, aweakercorrelationbetweentotalCSFapoEand
CSF Ab1-42 (s = 0.385, p= 0.105) was detected in e4 carriers
contrary to e4 non-carriers (s =0.310, p = 0.354), which is in
accordancewith a previous report fromMartinez-Morillo et al. [9].
Itwas foundthat apoE involved inAboligomerization [17,27]where
E4 isoform promotes Ab42 aggregation into senile plaques by
reducing its clearance [6]. Our results, however the associationwas
not signiﬁcant, also suggest isoform-speciﬁc interaction between
apoE and Ab.
No associations were found between AD biomarkers and apoE
concentration in plasma, although a slight decrease in plasma apoE
Table 4
Patient characteristics in the two cohorts.
Study cohort ID Age Gender%
(M/F)
MMSE score QAlb CSF T-tau (ng/L) CSF P-tau (ng/L) CSF Ab42 (ng/L)
Cohort A AD
n =13
75.3 (64–83) 21/79 26.5 (25–29) 8.1 (6.1–16.2) 685 (354–900)[17_TD$DIFF]a 91 (46–119)b 469 (353–562)
Non-AD
n =13
79.2 (57–89) 62/38 25.1 (21–29) 12.2 (5.4–41.7) 408 (180–730) [18_TD$DIFF]a 56 (29–104)b 502 (170–690)
Cohort B AD
n =26
75.3 (61–89) 54/46 25.0 (11–30) 6.1 (2.0–32.0) 591 (264–1110) – 534 (289–1060)
Non-AD
n =25
74.6 (58–88) 44/56 23.9 (17–30) 7.0 (3.1–13.7) 651 (252–1420) – 634 (272–1410)
[19_TD$DIFF]a signiﬁcant difference at p<0.001 level.
b signiﬁcant difference [20_TD$DIFF]at p<0.005 level.
[(Fig._3)TD$FIG]
B
A
Fig. 3. Association between CSF Ab42 and apoE levels in plasma (A) and in CSF (B). Individuals were divided into two groups based on CSF Ab42 level (low and high), cut-off
level was set to 500pg/mL. Non-AD subjects are represented by red dots and AD patients are represented by blue dots.
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levelwas detected in the group of patients with lowCSFAb42 level
in comparison with the high level group (Fig. 3). The same cut-off
level of Ab42 (500pg/mL) was used to distinguish the two groups
as in previous studies [9,28]. In contrary, we found no difference in
CSF apoE levels between the same groups of subjects, which is in
contrast with former publication from Cruchaga et al. [18].
4. Conclusions
In the current study we presented a highly speciﬁc mass
spectrometry-based assay for reliable quantiﬁcation of apoE
including its speciﬁc isoforms in biological ﬂuids. The assay allows
apoE phenotype determination with 100% accuracy. We showed
that neither CSF nor blood level of total apoE is enable to
differentiate AD patients from non-AD subjects. Additionally we
demonstrated that [28_TD$DIFF][14_TD$DIFF]APOE e4 carriers have lower levels of apoE in
blood independent of clinical diagnosis, which is in accordance
with previous studies [8,9]. We further showed correlation
between CSF apoE and P-tau levels in e4 non-carriers, and a weak
association between CSF apoE and CSF Ab1-42 concentrations in
e4 carriers only.
Further studies are needed to clarify contradictions in
publications concerning apoE ﬂuid levels in relation to AD, in
addition to determine themechanisms bywhich apoE isoforms are
involved in AD development.
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